T1	Post-eligibility 0 45	Inability to provide written informed consent
T2	Condition 70 91	intracranial bleeding
T3	Qualifier 64 69	prior
R1	Has_qualifier Arg1:T2 Arg2:T3	
T4	Drug 113 138	P2Y12 receptor antagonist
T5	Drug 140 151	ticlopidine
T6	Drug 153 164	clopidogrel
T7	Drug 166 175	prasugrel
T8	Drug 177 187	ticagrelor
T9	Scope 140 187	ticlopidine, clopidogrel, prasugrel, ticagrelor
R2	Subsumes Arg1:T4 Arg2:T9	
*	OR T5 T6 T7 T8
T10	Temporal 196 209	prior 10 days
R3	Has_temporal Arg1:T4 Arg2:T10	
T11	Condition 217 226	allergies
T12	Drug 230 237	aspirin
T13	Drug 239 249	ticagrelor
T14	Drug 253 262	cangrelor
*	OR T12 T13 T14
T15	Scope 230 262	aspirin, ticagrelor or cangrelor
R4	Has_scope Arg1:T11 Arg2:T15	
T16	Drug 287 300	anticoagulant
T17	Qualifier 282 286	oral
R5	Has_qualifier Arg1:T16 Arg2:T17	
T18	Drug 317 349	glycoprotein IIb/IIIa inhibitors
T19	Procedure 351 364	Fibrinolytics
T20	Temporal 365 380	within 24 hours
R6	Has_temporal Arg1:T19 Arg2:T20	
T21	Condition 382 397	Active bleeding
T22	Qualifier 399 408	High risk
T23	Condition 412 420	bleeding
R7	Has_qualifier Arg1:T23 Arg2:T22	
T24	Measurement 428 442	platelet count
T25	Value 443 453	<80x106/mL
R8	Has_value Arg1:T24 Arg2:T25	
T26	Measurement 461 471	hemoglobin
T27	Value 472 480	<10 g/dL
R9	Has_value Arg1:T26 Arg2:T27	
T28	Condition 482 491	Intubated
T29	Temporal 502 524	prior to randomization
T30	Reference_point 511 524	randomization
R10	Has_index Arg1:T29 Arg2:T30	
R11	Has_temporal Arg1:T28 Arg2:T29	
T31	Measurement 533 553	creatinine clearance
T32	Value 554 567	<30 mL/minute
R12	Has_value Arg1:T31 Arg2:T32	
T33	Procedure 574 586	hemodialysis
*	OR T31 T33
T34	Condition 602 621	hepatic dysfunction
T35	Qualifier 595 601	severe
R13	Has_qualifier Arg1:T34 Arg2:T35	
T36	Condition 637 656	sick sinus syndrome
T37	Condition 658 661	SSS
T38	Condition 678 686	AV block
T39	Qualifier 666 677	high degree
R14	Has_qualifier Arg1:T38 Arg2:T39	
T40	Procedure 695 704	pacemaker
T41	Negation 687 694	without
R15	Has_negation Arg1:T40 Arg2:T41	
R16	AND Arg1:T38 Arg2:T40	
R17	Subsumes Arg1:T36 Arg2:T37	
*	OR T36 T38
T42	Drug 740 745	drugs
T43	Condition 763 780	CYP3A4 metabolism
T44	Drug 808 818	ticagrelor
R18	AND Arg1:T42 Arg2:T43	
T45	Mood 746 762	interfering with
R19	Has_mood Arg1:T43 Arg2:T45	
T46	Drug 821 833	Ketoconazole
T47	Non-query-able 782 818	to avoid interaction with ticagrelor
T48	Drug 835 847	itraconazole
T49	Drug 849 861	voriconazole
T50	Drug 863 877	clarithromycin
T51	Drug 879 889	nefazodone
T52	Drug 891 900	ritonavir
T53	Drug 902 912	saquinavir
T54	Drug 914 924	nelfinavir
T55	Drug 926 935	indinavir
T56	Drug 937 947	atazanavir
T57	Drug 953 968	telithromizycin
*	OR T46 T48 T49 T50 T51 T52 T53 T54 T55 T56 T57
T58	Scope 821 968	Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin
R20	Subsumes Arg1:T42 Arg2:T58	
T59	Condition 971 979	Pregnant
T60	Condition 983 992	lactating
*	OR T59 T60
T61	Person 993 1000	females
A1	Optional T61
T62	Scope 971 992	Pregnant or lactating
R21	Has_scope Arg1:T61 Arg2:T62	
